Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

ClinicalTrials.gov ID: NCT06218914

Public ClinicalTrials.gov record NCT06218914. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 6, 2026, 8:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Open-label, Phase 1, Multi-Center Master Protocol to Evaluate the Safety and Preliminary Anti-Tumor Activity of TCR-engineered T Cells Recognizing KRAS Mutations in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors

Study identification

NCT ID: NCT06218914
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: AstraZeneca; Industry
Enrollment: 108 participants

Conditions and interventions

Conditions

Interventions

AZD0240: Autologous, engineered T Cells targeting KRAS G12D Biological
NT-112: Autologous, engineered T Cells targeting KRAS G12D Biological

Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 21, 2024
Primary completion: Aug 29, 2027
Completion: Nov 17, 2043
Last update posted: Apr 30, 2026

2024 – 2043

United States locations

U.S. sites: 18
U.S. states: 12
U.S. cities: 17

Facility	City	State	ZIP	Site status
Research Site	Duarte	California	91010	Recruiting
Research Site	Los Angeles	California	90095	Recruiting
Research Site	Newport Beach	California	92663	Recruiting
Research Site	Jacksonville	Florida	32224	Recruiting
Research Site	Chicago	Illinois	60637	Recruiting
Research Site	Westwood	Kansas	66205	Recruiting
Research Site	Boston	Massachusetts	02115	Recruiting
Research Site	St Louis	Missouri	63110	Recruiting
Research Site	New York	New York	10016	Recruiting
Research Site	New York	New York	10065	Not yet recruiting
Research Site	Portland	Oregon	97213	Recruiting
Research Site	Philadelphia	Pennsylvania	19107	Recruiting
Research Site	Pittsburgh	Pennsylvania	15237	Recruiting
Research Site	Nashville	Tennessee	37203	Recruiting
Research Site	Dallas	Texas	75246	Recruiting
Research Site	Galveston	Texas	77555	Recruiting
Research Site	Houston	Texas	77030	Recruiting
Research Site	Milwaukee	Wisconsin	53226	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06218914, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 30, 2026 · Synced May 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06218914 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →